Print  |  Close

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors


Active: Yes
Cancer Type: Bile Duct Cancer
Gynecologic Cancers
Ovarian Cancer
Prostate Cancer
NCT ID: NCT04972981
Trial Phases: Phase I Protocol IDs: ADCT-901-101 (primary)
NCI-2021-10797
2021-002292-19
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: ADC Therapeutics S.A.
NCI Full Details: http://clinicaltrials.gov/show/NCT04972981

Summary

The primary objectives of this study are to identify the recommended dose for expansion (RDE)
(and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the
safety and the tolerability of ADCT-901.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.